asthma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Severe asthma group: 1. Treatment situation: high-dose inhaled corticosteroids (ICS) or oral corticosteroids (OCS) (fluticasone > 1000mcg or equivalent), and another asthma control medication; 2. Asthma control: According to GINA guidelines, asthma is not controlled, and there are more than 3 of the following symptoms in the past 4 weeks: (1) Daytime symptoms >= 2 times/week; (2) Activities are restricted; (3) Nocturnal symptoms>=1/week; (4) The frequency of relief medication >= 2 times/week; (5) FEV1 = 2 times/year requiring high-dose oral corticosteroids, doubling the maintenance dose for more than 3 days or requiring hospitalization). 3. Asthma diagnosis: FEV1>=12% or absolute value >=200ml after inhalation of 400mcg salbutamol or presence of airway hyperresponsiveness or 2-day average PEF diurnal variation >8% or ICS, OCS, LABA and SABA FEV1 decreased by >= 12% and 200ml + history of recurrent asthma within 1 month during dose reduction. Mild to moderate asthma group 1. Treatment situation: low to moderate dose ICS ( 80% predicted value before using bronchodilator. 3. Partial asthma control: 1-2 of the following symptoms in the past 4 weeks: (1) Daytime symptoms >= 2 times/week; (2) Activities are restricted; (3) Nocturnal symptoms>=1/week; (4) The frequency of relief medication >= 2 times/week; (5) FEV1 =12% or absolute value >=200ml after inhalation of 400mcg salbutamol or presence of airway hyperresponsiveness or 2-day average PEF diurnal variation >8% or ICS, OCS, LABA and SABA FEV1 decreased by >= 12% and 200ml + history of recurrent asthma within 1 month during dose reduction. non-asthmatic control group 1. Treatment status: none; 2. Asthma control: FEV1>=80% predicted value in non-asthmatic patients; 3. Asthma diagnosis: no history of asthma, no history of other major diseases of the system.
Exclusion criteria
Exclusion criteria: 1. Current or previous smokers >10 years; 2. FEV1<1.0L after using bronchodilators; 3. Associated with other systemic serious diseases; 4. Contraindications for electronic bronchoscopy; 5. Unable to sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RNA;Protein; | — |
Countries
China
Contacts
The University of Hong Kong-Shenzhen Hospital